Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Melbourne, Australia.
Centre for Research Excellence in Digital Technology to Transform Chronic Disease Outcomes, National Health and Medical Research Council, Melbourne, Australia.
JMIR Res Protoc. 2024 Aug 7;13:e52973. doi: 10.2196/52973.
Cardiometabolic diseases (CMDs) are a group of interrelated conditions, including heart failure and diabetes, that increase the risk of cardiovascular and metabolic complications. The rising number of Australians with CMDs has necessitated new strategies for those managing these conditions, such as digital health interventions. The effectiveness of digital health interventions in supporting people with CMDs is dependent on the extent to which users engage with the tools. Augmenting digital health interventions with conversational agents, technologies that interact with people using natural language, may enhance engagement because of their human-like attributes. To date, no systematic review has compiled evidence on how design features influence the engagement of conversational agent-enabled interventions supporting people with CMDs. This review seeks to address this gap, thereby guiding developers in creating more engaging and effective tools for CMD management.
The aim of this systematic review is to synthesize evidence pertaining to conversational agent-enabled intervention design features and their impacts on the engagement of people managing CMD.
The review is conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and reported in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Searches will be conducted in the Ovid (Medline), Web of Science, and Scopus databases, which will be run again prior to manuscript submission. Inclusion criteria will consist of primary research studies reporting on conversational agent-enabled interventions, including measures of engagement, in adults with CMD. Data extraction will seek to capture the perspectives of people with CMD on the use of conversational agent-enabled interventions. Joanna Briggs Institute critical appraisal tools will be used to evaluate the overall quality of evidence collected.
This review was initiated in May 2023 and was registered with the International Prospective Register of Systematic Reviews (PROSPERO) in June 2023, prior to title and abstract screening. Full-text screening of articles was completed in July 2023 and data extraction began August 2023. Final searches were conducted in April 2024 prior to finalizing the review and the manuscript was submitted for peer review in July 2024.
This review will synthesize diverse observations pertaining to conversational agent-enabled intervention design features and their impacts on engagement among people with CMDs. These observations can be used to guide the development of more engaging conversational agent-enabled interventions, thereby increasing the likelihood of regular intervention use and improved CMD health outcomes. Additionally, this review will identify gaps in the literature in terms of how engagement is reported, thereby highlighting areas for future exploration and supporting researchers in advancing the understanding of conversational agent-enabled interventions.
PROSPERO CRD42023431579; https://tinyurl.com/55cxkm26.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/52973.
心脏代谢疾病（CMD）是一组相互关联的疾病，包括心力衰竭和糖尿病，这些疾病会增加心血管和代谢并发症的风险。越来越多的澳大利亚人患有 CMD，这就需要为这些患者制定新的管理策略，例如数字健康干预措施。数字健康干预措施在支持 CMD 患者方面的有效性取决于用户对这些工具的参与程度。通过使用自然语言与用户交互的会话代理等技术增强数字健康干预措施，可以通过其类似人类的属性提高用户的参与度。迄今为止，尚无系统评价综合了设计功能如何影响支持 CMD 患者的会话代理启用干预措施的参与度。本综述旨在解决这一差距，从而指导开发人员为 CMD 管理创建更具吸引力和更有效的工具。
本系统评价旨在综合与会话代理启用的干预设计特征及其对管理 CMD 的人群的参与度的影响相关的证据。
该综述按照 Cochrane 干预措施系统评价手册进行，并按照 PRISMA（系统评价和荟萃分析的首选报告项目）指南进行报告。将在 Ovid（Medline）、Web of Science 和 Scopus 数据库中进行检索，在提交手稿前将再次运行这些数据库检索。纳入标准将包括报告关于成年人 CMD 的会话代理启用干预措施以及参与度措施的主要研究。数据提取将试图捕捉 CMD 患者对使用会话代理启用的干预措施的看法。Joanna Briggs Institute 批判性评价工具将用于评估收集的证据的总体质量。
本综述于 2023 年 5 月启动，并于 2023 年 6 月在国际前瞻性系统评价注册处（PROSPERO）进行了注册，然后进行标题和摘要筛选。2023 年 7 月完成了文章的全文筛选，并于 2023 年 8 月开始数据提取。2024 年 4 月进行了最后一次检索，然后完成了综述，并于 2024 年 7 月提交同行评审。
本综述将综合有关会话代理启用的干预设计特征及其对 CMD 患者参与度的影响的各种观察结果。这些观察结果可用于指导更具吸引力的会话代理启用的干预措施的开发，从而增加常规干预措施使用的可能性并改善 CMD 的健康结果。此外，本综述将确定报告参与度的文献中的差距，从而突出未来探索的领域，并支持研究人员推进对会话代理启用的干预措施的理解。
PROSPERO CRD42023431579；https://tinyurl.com/55cxkm26。
国际注册报告标识符（IRRID）：DERR1-10.2196/52973。
